IGC Pharma (IGC) Interest & Investment Income (2010 - 2017)
IGC Pharma's (IGC) quarterly Interest & Investment Income came in at $100.0 in Q3 2017, down 12.28% year-over-year from $114.0 in Q3 2016, and down 12.28% quarter-over-quarter from $114.0 in Q3 2016.
Powered by 
Analysis
IGC Pharma (IGC) Interest & Investment Income (2010 - 2017) Analysis & Trends
IGC Pharma (IGC) has reported Interest & Investment Income for 8 consecutive years, with $100.0 the latest figure, recorded in Q3 2017.
- On a quarterly basis, Interest & Investment Income fell 12.28% year-over-year to $100.0 in Q3 2017; TTM through Sep 2017 was $2228.0, a 1.36% increase from a year earlier, with the FY2017 full-year figure at $1744.0, down 16.35% from the prior year.
- Interest & Investment Income was $100.0 for Q3 2017 at IGC Pharma, down from $114.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $27509.0 in Q1 2013 and troughed at $70.0 in Q4 2015.
- A 5-year average of $3572.3 and a median of $1919.0 in 2013 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income soared 387.46% in 2013 and plunged 95.65% in 2015, its largest moves.
- Over 5 years, Interest & Investment Income stood at $1824.0 in 2013, then decreased by 11.73% to $1610.0 in 2014, then sank by 95.65% to $70.0 in 2015, then soared by 62.86% to $114.0 in 2016, then slipped by 12.28% to $100.0 in 2017.
- The last three Interest & Investment Income figures came in at $100.0 (Q3 2017), $114.0 (Q3 2016), and $2014.0 (Q1 2016), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.74 Bn | 192.75 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.96 Bn | 176.78 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 131.20 Bn | 123.35 Bn | 2.84 Bn | 120.60 Mn |
| 4 | Regeneron Pharmaceuticals | 82.05 Bn | 74.05 Bn | 3.93 Bn | -48.00 Mn |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn | 48.00 Mn |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn | 67.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.08 Bn | 29.78 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Biogen | 31.91 Bn | 30.62 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.22 Bn | 29.22 Bn | 1.16 Mn | 36.92 Mn |
| 10 | IGC Pharma | 27.58 Mn | 27.32 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2017 | 100.00 |
| Sep 30, 2016 | 114.00 |
| Mar 31, 2016 | 2,014.00 |
| Dec 31, 2015 | 70.00 |
| Jun 30, 2015 | 694.00 |
| Mar 31, 2015 | 2,715.00 |
| Dec 31, 2014 | 1,610.00 |
| Sep 30, 2014 | 136.00 |
| Jun 30, 2014 | 2,338.00 |
| Mar 31, 2014 | 4,555.00 |
| Dec 31, 2013 | 1,824.00 |
| Sep 30, 2013 | 2,253.00 |
| Jun 30, 2013 | 4,080.00 |
| Mar 31, 2013 | 27,509.00 |
| Dec 31, 2012 | 2,051.00 |
| Jun 30, 2012 | 837.00 |
| Mar 31, 2012 | 81,131.00 |
| Dec 31, 2011 | 59,629.00 |
| Sep 30, 2011 | 59,085.00 |
| Jun 30, 2011 | 67,348.00 |